Travere Therapeutics, Inc. TVTX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s accounts receivable?
- Travere Therapeutics, Inc. (TVTX) reported accounts receivable of $87.3M in Q1 2026.
- How has Travere Therapeutics, Inc.'s accounts receivable changed year-over-year?
- Travere Therapeutics, Inc.'s accounts receivable increased by 153.9% year-over-year, from $34.38M to $87.3M.
- What is the long-term trend for Travere Therapeutics, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s accounts receivable has grown at a 38.1% compound annual growth rate (CAGR), from $15.93M to $80.13M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.